Evidence map›Paper›PMID 40277892›Full record

ReviewCells2025

Thinking Outside the Therapeutic Box: The Potential of Polyphenols in Preventing Chemotherapy-Induced Endothelial Dysfunction.

Luke Tillman, Jaume Margalef Rieres, Elena Ahjem, Fynn Bishop-Guest, Meghan McGrath, Helena Hatrick, Md Zahidul Islam Pranjol

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Potential Role of Polyphenols in Platelet Aggregation and Blood Coagulation.Journal of cardiovascular development and disease · 2026
    Review
  2. Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update.Journal of cardiovascular development and disease · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luke TillmanSchool of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK.ORCID 0000-0002-1439-0682
Jaume Margalef RieresSchool of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK.
Elena AhjemSchool of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK.ORCID 0009-0005-2198-4277
Fynn Bishop-GuestSchool of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK.
Meghan McGrathSchool of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK.ORCID 0009-0005-1872-0035
Helena HatrickSchool of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK.
Md Zahidul Islam PranjolSchool of Life Sciences, University of Sussex, Falmer, Brighton BN1 9QG, UK.ORCID 0000-0002-6164-6281

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The numerous side effects and adverse health implications associated with chemotherapies have long plagued the field of cancer care. Whilst in some cases a curative measure, this highly toxic intervention consistently scores poorly on quantitative measures of tolerability and safety. Of these side effects, cardiac and microvascular defects pose the greatest health risk and are the leading cause of death amongst cancer survivors who do not succumb to relapse. In fact, in many low-grade cancers, the risk of recurrence is far outweighed by the cardiovascular risk of morbidity. As such, there is a pressing need to improve outcomes within these populations. Polyphenols are a group of naturally occurring metabolites that have shown potential vasoprotective effects. Studies suggest they possess antioxidant and anti-inflammatory activities, in addition to directly modulating vascular signalling pathways and gene expression. Leveraging these properties may help counteract the vascular toxicity induced by chemotherapy. In this review, we outline the main mechanisms by which the endothelium is damaged by chemotherapeutic agents and discuss the ability of polyphenols to counteract such side effects. We suggest future considerations that may help overcome some of the published limitations of these compounds that have stalled their clinical success. Finally, we briefly explore their pharmacological properties and how novel approaches could enhance their efficacy while minimising treatment-related side effects.

Indexed as

Antineoplastic AgentsEndothelium, VascularNeoplasmsPolyphenolsAnimalsAntioxidantsHumansAntineoplastic AgentsAntioxidantsPolyphenolscancercardiovascular diseasechemotherapyendothelial dysfunctionendotheliumpolyphenols

Identifiers

PMID40277892
PMCPMC12026109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.